Posters Archives

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

Invivoscribe Marketing2021-03-05T20:49:11-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

Invivoscribe Marketing2021-03-05T20:44:34-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

Invivoscribe Marketing2021-03-05T20:38:02-08:00March 5th, 2021|2019 Posters, AMP, Posters|

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

Invivoscribe Marketing2021-03-03T23:53:52-08:00March 3rd, 2021|2019 Posters, AMP, Posters|

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

Invivoscribe Marketing2021-03-03T23:55:00-08:00March 3rd, 2021|2020 Posters, EHA, Posters|

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

Invivoscribe Marketing2021-03-03T23:40:33-08:00March 3rd, 2021|2020 Posters, ASH, Posters|

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

Title

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

AMP Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP Comparing DNA Extraction Methods for the LymphoTrack® IVD TRG Assay

AMPA Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHATRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASHEnd of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

AMP

Validation of an NGS based assay for monitoring FLT3 ITD and TKD variants in AML subjects

AMP

Evaluation of An Alternative Fragmentation Method in High Throughput NGS Sample Testing of Minimal Residual Disease in Hematological Malignancies

AMP

Comparing DNA Extraction Methods for the LymphoTrack^® IVD TRG Assay

AMP

A Next-Generation Sequencing Based Analysis of Clonality across 39 Subjects Treated for Lymphoproliferative Disorders Reveals Matching Clones in the Diverse IGH Locus

EHA

TRG Clonality Interrogation by CE and NGS: Bridging the Gap Between Classical and Leading Edge Technologies

ASH

End of Treatment Peripheral Blood TCR Evaluation for Minimal Residual Disease Evaluation in Peripheral T-cell Lymphomas